MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 524277 | Name: ASP-8497

Description:

WARNING: This product is for research use only, not for human or veterinary use.

ASP8497 is a potent and long-acting DPP-IV inhibitor and improves glucose tolerance through glucose-dependent insulinotropic action via elevation of the GLP-1 level. This compound is used as a therapeutic agent for impaired glucose tolerance and type 2 diabetes.

Chemical Structure

ASP-8497
ASP-8497
CAS#651055-26-4(butenedioate)

Theoretical Analysis

MedKoo Cat#: 524277

Name: ASP-8497

CAS#: 651055-26-4(butenedioate)

Chemical Formula: C18H27FN4O7S

Exact Mass: 462.1585

Molecular Weight: 462.49

Elemental Analysis: C, 46.75; H, 5.88; F, 4.11; N, 12.11; O, 24.22; S, 6.93

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
651055-26-4(butenedioate) 651055-25-3 (free base)
Synonym
ASP-8497; ASP 8497; ASP8497;
IUPAC/Chemical Name
2-Pyrrolidinecarbonitrile, 4-fluoro-1-(((4-methyl-1-(methylsulfonyl)-4-piperidinyl)amino)acetyl)-, (2S,4S)-, (2E)-2-butenedioate (1:1)
InChi Key
YZYBLEWOKAXTOL-QPPPMHOJSA-N
InChi Code
InChI=1S/C14H23FN4O3S.C4H4O4/c1-14(3-5-18(6-4-14)23(2,21)22)17-9-13(20)19-10-11(15)7-12(19)8-16;5-3(6)1-2-4(7)8/h11-12,17H,3-7,9-10H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1+/t11-,12-;/m0./s1
SMILES Code
CC1(CCN(CC1)S(=O)(=O)C)NCC(=O)N2C[C@H](C[C@H]2C#N)F.C(=C/C(=O)O)\C(=O)O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Related: 651055-26-4(ASP-8497) 651055-25-3 (ASP-8497 free base)

Preparing Stock Solutions

The following data is based on the product molecular weight 462.49 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Tahara A, Matsuyama-Yokono A, Nakano R, Someya Y, Hayakawa M, Shibasaki M. Antihyperglycemic effects of ASP8497 in streptozotocin-nicotinamide induced diabetic rats: comparison with other dipeptidyl peptidase-IV inhibitors. Pharmacol Rep. 2009 Sep-Oct;61(5):899-908. PubMed PMID: 19904014. 2: Someya Y, Nakano R, Tahara A, Takasu T, Takeuchi A, Nagase I, Matsuyama-Yokono A, Hayakawa M, Sasamata M, Miyata K, Uchiyama Y. Effects of the dipeptidyl peptidase-IV inhibitor ASP8497 on glucose tolerance in animal models of secondary failure. Eur J Pharmacol. 2009 Nov 10;622(1-3):71-7. doi: 10.1016/j.ejphar.2009.09.024. Epub 2009 Sep 17. PubMed PMID: 19766107. 3: Matsuyama-Yokono A, Tahara A, Nakano R, Someya Y, Shiraki K, Hayakawa M, Shibasaki M. Antidiabetic effects of dipeptidyl peptidase-IV inhibitors and sulfonylureas in streptozotocin-nicotinamide-induced mildly diabetic mice. Metabolism. 2009 Mar;58(3):379-86. doi: 10.1016/j.metabol.2008.10.012. PubMed PMID: 19217455. 4: Tahara A, Matsuyama-Yokono A, Nakano R, Someya Y, Hayakawa M, Shibasaki M. Evaluation of the antidiabetic effects of dipeptidyl peptidase-IV inhibitor ASP8497 in streptozotocin-nicotinamide-induced mildly diabetic mice. Pharmacology. 2009;83(3):177-87. doi: 10.1159/000196813. Epub 2009 Jan 29. PubMed PMID: 19176982. 5: Tahara A, Matsuyama-Yokono A, Nakano R, Someya Y, Hayakawa M, Shibasaki M. Effects of the combination of dipeptidyl peptidase-IV inhibitor ASP8497 and antidiabetic drugs in streptozotocin-nicotinamide-induced mildly diabetic mice. Eur J Pharmacol. 2009 Mar 1;605(1-3):170-6. doi: 10.1016/j.ejphar.2008.12.040. Epub 2009 Jan 10. PubMed PMID: 19171131. 6: Matsuyama-Yokono A, Tahara A, Nakano R, Someya Y, Hayakawa M, Shibasaki M. Chronic inhibition of dipeptidyl peptidase-IV with ASP8497 improved the HbA(1c) level, glucose intolerance, and lipid parameter level in streptozotocin-nicotinamide-induced diabetic mice. Naunyn Schmiedebergs Arch Pharmacol. 2009 Feb;379(2):191-9. doi: 10.1007/s00210-008-0348-x. Epub 2008 Sep 2. PubMed PMID: 18762913. 7: Matsuyama-Yokono A, Tahara A, Nakano R, Someya Y, Nagase I, Hayakawa M, Shibasaki M. ASP8497 is a novel selective and competitive dipeptidyl peptidase-IV inhibitor with antihyperglycemic activity. Biochem Pharmacol. 2008 Jul 1;76(1):98-107. doi: 10.1016/j.bcp.2008.03.021. Epub 2008 Apr 6. PubMed PMID: 18468582. 8: Someya Y, Tahara A, Nakano R, Matsuyama-Yokono A, Nagase I, Fukunaga Y, Takasu T, Hayakawa M, Shibasaki M. Pharmacological profile of ASP8497, a novel, selective, and competitive dipeptidyl peptidase-IV inhibitor, in vitro and in vivo. Naunyn Schmiedebergs Arch Pharmacol. 2008 May;377(3):209-17. doi: 10.1007/s00210-008-0277-8. Epub 2008 Apr 9. PubMed PMID: 18398600.